Diversifying the xanthine scaffold for potential phosphodiesterase 9A inhibitors: synthesis and validation
Tóm tắt
Xanthine and its derivatives have been a great area of interest for the development of potent bioactive agents. In this study, two synthesis routes have been developed for 1,3,8-tri substituted xanthine derivatives. The synthesis routes exploits “xanthine” as precursor molecule as it represents maximum unsubstituted sites for maximum possible substitutions. This study divulged the reactivity pattern of three –NH groups at N1, N3 and N7 position of xanthine in the order of N7 > N3 > N1, which helped in carrying out regio-selective N-alkylation reaction at different –NH sites of xanthine. Selective protection and selective deprotection at N3 and/or N7 sites of xanthine were the key strategies for developing two synthesis schemes. Eight newly synthesized compounds C1-8 were evaluated for their biological activity against Phosphodiesterase 9A. All the compounds were found to be promising inhibitors. To gain further insight for mode of interaction with Phosphodiesterase 9A, these compounds were subjected to docking studies. The present study provides insight into the potential of ‘xanthine’ to contribute to the structural diversification of xanthine derivatives in the drug development process. Xanthine based chemical synthesis is shown to be a cost effective, fast, and highly productive method. This work can be extrapolated to find various selective xanthine based inhibitors targeting other enzymes.
Tài liệu tham khảo
Dai ZK, Liu YW, Hsu JH, Yeh JL, Chen IJ, Wu JR, et al. The xanthine derivative KMUP-1 attenuates serotonin-induced vasoconstriction and K+-channel inhibitory activity via the PKC pathway in pulmonary arteries. Int J Biol Sci. 2015;11:633–42.
Hosseinzadeh H, Fazly Bazzaz BS, Moaddab Sadati M. In vitro evaluation of methylxanthines and some antibiotics: interaction against Staphylococcus aureus and Pseudomonas aeruginosa. Iran Biomed J. 2006;10:163–7.
Kadi AA, El-Tahir KEH, Jahng Y, Rahman AFMM. Synthesis, biological evaluation and Structure Activity Relationships (SARs) study of 8-(substituted)aryloxycaffeine. Arab J Chem. 2015;12:2356–64.
Laddha SS, Wadodkar SG, Meghal SK. CAMP-dependent phosphodiesterase inhibition and SAR studies on novel 6,8-disubstituted 2-phenyl-3-(substituted benzothiazole-2-yl)-4[3H]- quinazolinone. Med Chem Res. 2009;18:268–76.
van Galen PJM, Stiles GL, Michaels G, Jacobson KA. Adenosine A1 and A2 receptors: structure-function relationships. Med Res Rev. 1992;12:423–71.
Burbiel JC, Hockemeyer J, Müller CE. Microwave-assisted ring closure reactions: synthesis of 8-substituted xanthine derivatives and related pyrimido- and diazepinopurinediones. Beilstein J Org Chem. 2006;63:1–6.
Singh N, Shreshtha AK, Thakur MS, Patra S. Xanthine scaffold: scope and potential in drug development. Heliyon. 2018;4:e00829.
McCarthy AA, McCarthy JG. The structure of two N-methyltransferases from the caffeine biosynthetic pathway. Plant Physiol. 2007;144:879–89.
Baraldi PG, Fruttarolo F, Tabrizi MA, Romagnoli R, Preti D. Novel 8-heterocyclyl xanthine derivatives in drug development - an update. Expert Opin Drug Disco. 2007;2:1161–83.
Abdulrahman LK, Al-Mousilly MM, Al-Halaibeh TS, Al-Azzawii KM. International research journal of pharmacy synthesis of new 1, 3, 7, 8-tetrasubstituted xanthenes analogue. Int Res J Pharm. 2012;3:83–85.
Allwood MB, Cannan B, van Aalten DMF, Eggleston IM. Efficient synthesis of 1,3,7-substituted xanthines by a safety-catch protection strategy. Tetrahedron. 2007;63:12294–302.
Bandyopadhyay P, Agrawal SK, Sathe M, Sharma P, Kaushik MP. A facile and rapid one-step synthesis of 8-substituted xanthine derivatives via tandem ring closure at room temperature. Tetrahedron. 2012;68:3822–7.
Cassidy F, Olsen RK, Robins RK. Aromaticity in heterocyclic systems V. Bromination studies of certain purine, pyrrolo [3,2-d] pyramidines and pyrazolo [4,3-d] pyramidines. J Heterocycl Chem. 1968;5:461–5.
Chen Y, Wang B, Guo Y, Zhou Y, Pan L, Xiong L, et al. Synthesis and biological activities of novel methyl xanthine derivatives. Chem Res Chin Univ. 2014;30:98–102.
Hayallah AM, Sandoval-Ramírez J, Reith U, Schobert U, Preiss B, Schumacher B, et al. 1,8-disubstituted xanthine derivatives: synthesis of potent a2b-selective adenosine receptor antagonists. J Med Chem. 2002;45:1500–10.
Ivanov EI, Polishchuk AA, Kalayanov GD. Synthesis of crown-containing xanthine derivatives. Chem Heterocycl Compd. 1992;28:1266–9.
Kim D, Jun H, Lee H, Hong SS, Hong S. Development of new fluorescent xanthines as kinase inhibitors. Org Lett 2010;12:1212–5.
Lee D, Lee S, Liu KH, Bae JS, Baek DJ, Lee T. Solid-phase synthesis of 1,3,7,8-tetrasubstituted xanthine derivatives on traceless solid support. ACS Comb Sci. 2016;18:70–74.
Sakai R, Konno K, Yamamoto Y, Sanae F, Takagi K, Hasegawa T, et al. Effects of alkyl substitutions of xanthine skeleton on bronchodilation. J Med Chem. 1992;35:4039–44.
Fisher DA, Smith JF, Pillar JS, St Denis SH, Cheng JB. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J Biol Chem. 1998;273:15559–64.
Li Z, Lu X, Feng LJ, Gu Y, Li X, Wu Y, et al. Molecular dynamics based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds. Mol BioSyst. 2015;11:115–25.
Rentero C, Monfort A, Puigdomènech P. Identification and distribution of different mRNA variants produced by differential splicing in the human phosphodiesterase 9A gene. Biochem Biophys Res Commun. 2003;301:686–92.
Ke H, Wang H, Ye M. Structural insight into the substrate specificity of phosphodiesterases. Handb Exp Pharmacol. 2011;204:121–34.
Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Disco. 2014;13:290–314.
Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res. 2007;100:309–27.
Shao Y, Huang M, Cui W, Feng LJ, Wu Y, Cai Y, et al. Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic Agent. J Med Chem. 2014;57:10304–13.
Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481–511.
Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharm. 2005;68:1775–81.
Singh N, Patra S. Phosphodiesterase 9: Insights from protein structure and role in therapeutics. Life Sci. 2014;106:1–11.
Meng F, Hou J, Shao YX, Wu PY, Huang M, Zhu X, et al. Structure-based discovery of highly selective Phosphodiesterase-9A inhibitors and implications for inhibitor design. J Med Chem. 2012;55:8549–58.
Verhoest PR, Fonseca KR, Hou X, Proulx-LaFrance C, Corman M, Helal CJ. et al. Design and discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant pde9a inhibitor for the treatment of cognitive disor. J Med Chem. 2012;55:9045–54.
Claffey MM, Helal CJ, Verhoest PR, Kang Z, Fors KS, Jung S, et al. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active Phosphodiesterase 9A inhibitors. J Med Chem. 2012;55:9055–68.
Singh N, Saravanan P, Thakur MS, Patra S. Development of xanthine based inhibitors targeting Phosphodiesterase 9A. Let Drug Des Dis. 2017;14:1122–37.
Gulevskaya AV, Pozharskii AF. Synthesis of N-substituted xanthines (review). Chem Heterocycl Compd. 1991;27:1–23.
Sanae F, Ohmae S, Kurita M, Sawanishi H, Takagi K, Miyamotol KI. Structure-activity relationships of alkylxanthines: alkyl chain elongation at the N1- or N7-position decreases cardiotonic activity in the isolated guinea pig heart. Jpn J Pharm. 1995;69:75–82.
Feng J, Chen Y, Pu J, Yang X, Zhang C, Zhu S, et al. An improved malachite green assay of phosphate: Mechanism and application. Anal Biochem. 2011;409:144–9.
Zhu S, Gan Z, Li Z, Liu Y, Yang X, Deng P, et al. The measurement of cyclic nucleotide phosphodiesterase 4 activities via the quantification of inorganic phosphate with malachite green. Anal Chim Acta. 2009;636:105–10.
Huai Q, Wang H, Zhang W, Colman RW, Robinson H, Ke H. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc Natl Acad Sci USA. 2004;101:9624–9.
Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007;2:2212–21.
Singh N, Patra S, Patra S. Identification of xanthine derivatives as inhibitors of phosphodiesterase 9A through in silico and biological Studies. Comb Chem High Throu Scr. 2018;21:1–11.
He R, Ching SM, Lam Y. Traceless solid-phase synthesis of substituted xanthines. J Comb Chem. 2006;8:923–8.
Lin K, Cai Z, Wang F, Zhang W, Zhou W. Synthesis and biological evaluation of xanthine derivatives on dipeptidyl peptidase 4. Chem Pharm Bull. 2013;61:477–82.